Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer

1

Differentiated advanced thyroid carcinoma (DATC) accounts for approximately 5% of thyroid tumors and has a poor prognosis with a 10-year survival rate of around 10%.
2

Patients with locoregional disease showed significantly worse disease-specific survival compared to those with distant metastases, highlighting divergent prognostic outcomes.
3

The study analyzed 43 patients with radioiodine-refractory thyroid carcinoma treated with tyrosine kinase inhibitors, focusing on disease extent at treatment initiation.
4

At last follow-up, 62.8% of patients were alive, while 37.2% had died of the disease, indicating the high mortality associated with DATC.
5

Tailored management strategies are necessary for DATC patients, particularly to address the distinct challenges posed by locoregional versus distant metastatic disease.

Frontiers In Endocrinology

by Giulia Sapuppo, Marco Russo, Grete Francesca Privitera, Michele Massimino, Sebastiano Piana, Maria Antonietta Trovato, Giusi Blanco, Davide Adinolfi, Giorgia Romano, Gabriella Pellegriti
June 11, 2026

1